Advertisement

Heat Shock Protein 90 Versus Conventional Growth Factors in Acute and Diabetic Wound Healing

  • Wei Li
  • Kathryn O’Brien
  • David T. Woodley
  • Mei Chen
Chapter
Part of the Heat Shock Proteins book series (HESP, volume 6)

Abstract

Diabetic foot lesions are responsible for more hospitalizations than any other complication of diabetes in the United States of America. The number of diabetic foot ulcer-caused lower limb amputations is approaching 100,000/year, a rapid increase due to an aging population and the rising incidence of obesity. Cost-effect treatments are currently limited. For decades, the conventional wisdom is that growth factors constitute the driving forces of wound healing. Therefore, more than 30 growth factors have been extensively studied in animal models and a dozen of these growth factors have been subjected to clinical trials. Only PDGF-BB received the US FDA approval for treatment of diabetic ulcers in 1997. However, the modest efficacy, high cost and risks of causing cancer by PDGF-BB (becaplermin gel) have limited its use in clinical practice. This reality continues to be overlooked or ignored. An unconventional wound-healing molecule, extracellular heat shock protein-90alpha (eHsp90α), has recently been reported. Unlike restricted cell type specificity of PDGF-BB, eHsp90α is a common pro-motility factor of all skin cells, eHsp90α also overrides TGFβ inhibition and hyperglycemia. Topical application of eHsp90α accelerated both acute and diabetic wound closure far more effectively than PDGF-BB. We discuss what makes Hsp90α superior to conventional growth factors in wound healing.

Keywords

Wound Healing Transform Growth Factor Dermal Fibroblast Wound Edge Dermal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This study was supported by NIH grant GM/AR066193-01 (to W. L.) and AR46538 (to D. T. W.).

References

  1. Alvarez OM, Meehan M, Ennis W, Thomas DR, Ferris FD, Kennedy KL, Rogers R, Bradley M, Baker JJ, Fernandez-Obregon A, Rodeheaver G (2002) Chronic wounds: palliative management for the frail population. Wounds 14(p Suppl):713–732Google Scholar
  2. Bandyopadhyay B, Fan JF, Guan SX, Li Y, Fedesco M, Chen M, Woodley DT, Li W (2006) A “traffic control” role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J Cell Biol 172:1093–1105PubMedCrossRefGoogle Scholar
  3. Basu, S, Srivastava PF (2000) Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress Chaperones 5:443–451PubMedCrossRefGoogle Scholar
  4. Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303–313PubMedCrossRefGoogle Scholar
  5. Bejcek BE et al (1992) The v-sis oncogene product but not platelet-derived growth factor (PDGF) A homodimers activate PDGF alpha and beta receptors intracellularly and initiate cellular transformation. J Biol Chem 267:3289–3293PubMedGoogle Scholar
  6. Botusan IR, Sunkari VG, Savu O, Catrina AI, Grünler J, Lindberg S, Pereira T, Ylä-Herttuala S, Poellinger L, Brismar K, Catrina SB (2008) Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A 105:19426–19431PubMedCrossRefGoogle Scholar
  7. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J (2005) The global burden of diabetic foot disease. Lancet 366:1719–1724PubMedCrossRefGoogle Scholar
  8. Brown GL et al (1989) Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 321:76–79PubMedCrossRefGoogle Scholar
  9. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRefGoogle Scholar
  10. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L (2004) Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 53:3226–3232PubMedCrossRefGoogle Scholar
  11. Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC, Huang TS (2010) Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. J Biol Chem 285:25458–25466PubMedCrossRefGoogle Scholar
  12. Cheng CF et al (2008) Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol Cell Biol 28:3344–3358PubMedCrossRefGoogle Scholar
  13. Cheng CF et al (2011) A fragment of secreted from Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice. J Clin Invest 121:4348–4361Google Scholar
  14. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z (2005) Induction of heat shock proteins in B-cell exosomes. J Cell Sci 118:3631–3638PubMedCrossRefGoogle Scholar
  15. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79:129–68PubMedCrossRefGoogle Scholar
  16. Elson DA, Ryan HE, Snow JW, Johnson R, Arbeit JM (2000) Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res 60:6189–6195PubMedGoogle Scholar
  17. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6:507–514Google Scholar
  18. Fadini GP, Sartore S, Schiavon M, Albiero M, Baesso I, Cabrelle A, Agostini C, Avogaro A (2006) Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 49:3075–3084PubMedCrossRefGoogle Scholar
  19. Fernandez-Montequin JI et al (2007) Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 4:333–343PubMedGoogle Scholar
  20. Fu X et al (1998) Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 352:1661–1664PubMedCrossRefGoogle Scholar
  21. Gao Z, Sasaoka T, Fujimori T, Oya T, Ishii Y, Sabit H, Kawaguchi M, Kurotaki Y, Naito M, Wada T, Ishizawa S, Kobayashi M, Nabeshima Y, Sasahara M (2005) Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J Biol Chem 280:9375–9389PubMedCrossRefGoogle Scholar
  22. Gao W, Ferguson G, Connell P, Walshe T, Murphy R, Birney YA, O’Brien C, Cahill PA (2007) High glucose concentrations alter hypoxia-induced control of vascular smooth muscle cell growth via a HIF-1alpha-dependent pathway. J Mol Cell Cardiol 42:609–619PubMedCrossRefGoogle Scholar
  23. Greenhalgh DG, Rieman M (1994) Effects of basic fibroblast growth factor on the healing of partial-thickness donor sites. A prospective, randomized, double-blind trial. Wound Repair Regen 2:113–121PubMedCrossRefGoogle Scholar
  24. Grose R, Werner S (2004) Wound-healing studies in transgenic and knockout mice. Mol Biotechnol 28:147–166PubMedCrossRefGoogle Scholar
  25. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRefGoogle Scholar
  26. Habich C, Baumgart K, Kolb H, Burkart V (2000) The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J Immunol 168:569–576Google Scholar
  27. Hamed S, Brenner B, Abassi Z, Aharon A, Daoud D, Roguin A (2010) Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb Res 126:166–174PubMedCrossRefGoogle Scholar
  28. Harrington C, Zagari MJ, Corea J, Klitenic J (2000) A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 23:1333–1338PubMedCrossRefGoogle Scholar
  29. Hightower LE, Guidon PT Jr (1989) Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol 138:257–266PubMedCrossRefGoogle Scholar
  30. Knighton DR, Silver IA, Hunt TK (1981) Regulation of wound-healing angiogenesis-effect of oxygen gradients and inspired oxygen concentration. Surgery 90:262–270PubMedGoogle Scholar
  31. Kuroita TH, Tachibana H, Ohashi S, Shirahata H, Murakami (1992) Growth stimulating activity of heat shock protein 90 alpha to lymphoid cell lines in serum-free medium. Cytotechnology 8(1992):109–117Google Scholar
  32. Lancaster GI, Febbraio MA (2005) Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem 280:23349–23355PubMedCrossRefGoogle Scholar
  33. LeGrand EK (1998) Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. Am J Surg 176:48S–54SPubMedCrossRefGoogle Scholar
  34. Li W, Li Y, Guan S, Fan J, Cheng C, Bright A, Chin C, Chen M, Woodley DT (2007) Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J 26:1221–1233PubMedCrossRefGoogle Scholar
  35. Li W, Sahu D, Tsen F (2012) Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochim Biophys Acta 1823:730–741Google Scholar
  36. Liao DF et al (2000) Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 275:189–196PubMedCrossRefGoogle Scholar
  37. Lillis AP, Mikhailenko I, Strickland DK (2005) Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost 3:1884–1893PubMedCrossRefGoogle Scholar
  38. Lynch SE, Nixon JC, Colvin RB, Antoniades HN (1987) Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci U S A 84:7696–7700PubMedCrossRefGoogle Scholar
  39. Ma B et al (2007) Randomized, multicenter, double-blind, and placebo-controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial-thickness burns and skin graft donor site. Wound Repair Regen 15:795–799PubMedCrossRefGoogle Scholar
  40. Mandracchia VJ, Sanders SM, Frerichs JA (2001) The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis. Clin Podiatr Med Surg 18:189–209PubMedGoogle Scholar
  41. Martin P (1997) Wound healing-aiming for perfect skin regeneration. Science 276:75–81PubMedCrossRefGoogle Scholar
  42. Mandracchia VJ, Sanders SM, Frerichs JA (2001) The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis. Clin Podiatr Med Surg 18:189–209 (viii)PubMedGoogle Scholar
  43. Mascardo RN (1988) The effects of hyperglycemia on the directed migration of wounded endothelial cell monolayers. Metabolism 37:378–85PubMedCrossRefGoogle Scholar
  44. Mohan VK (2006) Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. Diabetes Res Clin Pract 78:405–411CrossRefGoogle Scholar
  45. Multhoff G, Hightower LE (1996) Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones 1:167–176PubMedCrossRefGoogle Scholar
  46. Nagai MK, Embil JM (2002) Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2:211–218PubMedCrossRefGoogle Scholar
  47. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 194:81–795CrossRefGoogle Scholar
  48. Olerud JE (2008) Models for diabetic wound healing and healing into percutaneous devices. J Biomater Sci Polym Ed 19:1007–1020PubMedCrossRefGoogle Scholar
  49. Pastor JC, Calonge M (1992) Epidermal growth factor and corneal wound healing. A multicenter study. Cornea 11:311–314PubMedCrossRefGoogle Scholar
  50. Peppa M, Stavroulakis P, Raptis SA (2009) Advanced glycoxidation products and impaired diabetic wound healing. Wound Repair Regen 17:461–472PubMedCrossRefGoogle Scholar
  51. Pierce GF, Tarpley JE, Yanagihara D, Mustoe TA, Fox GM, Thomason A (1992) Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair. Am J Pathol 140:1375–1388PubMedGoogle Scholar
  52. Poon E et al (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 11:e26PubMedCrossRefGoogle Scholar
  53. Ramsay HA, Heikkonen EJ, Laurila PK (1995) Effect of epidermal growth factor on tympanic membranes with chronic perforations: a clinical trial. Otolaryngol Head Neck Surg 113:375–379PubMedCrossRefGoogle Scholar
  54. Robson MC, Hill DP, Smith PD, Wang X, Meyer-Siegler K, Ko F, VandeBerg JS, Payne WG, Ochs D, Robson LE (2000) Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg 231:600–611PubMedCrossRefGoogle Scholar
  55. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH (1999) Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 7:335–346PubMedCrossRefGoogle Scholar
  56. Semenza GL (2007a) Life with oxygen. Science 318:62–64CrossRefGoogle Scholar
  57. Semenza GL (2007b) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12:853–869CrossRefGoogle Scholar
  58. Sen CK et al (2009) Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 17:763–771PubMedCrossRefGoogle Scholar
  59. Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738–746PubMedCrossRefGoogle Scholar
  60. Steed DL (1995) Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 21:71–78 (discussion 79–81)PubMedCrossRefGoogle Scholar
  61. Suzuki S, Kulkarni AB (2010) Extracellular heat shock protein HSP90beta secreted by MG63 osteosarcoma cells inhibits activation of latent TGF-beta1. Biochem Biophys Res Commun 398:525–5331PubMedCrossRefGoogle Scholar
  62. Tandara AA, Mustoe TA (2004) Oxygen in wound healing-more than a nutrient. World J Surg 28:294–300PubMedCrossRefGoogle Scholar
  63. Tredget EE, Nedelec B, Scott PG, Ghahary A (1997) Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am 77:701–730PubMedCrossRefGoogle Scholar
  64. Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S, Carreras C, Neckers L (2008) A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27:2478–2487PubMedCrossRefGoogle Scholar
  65. Uchi H et al (2009) Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol 19:461–468PubMedGoogle Scholar
  66. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 169:3978–3986PubMedGoogle Scholar
  67. Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G, Luo Y (2009) The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A 106:21288–21293PubMedCrossRefGoogle Scholar
  68. Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:835–870PubMedGoogle Scholar
  69. Wieman TJ, Smiell JM, Su Y (1998) Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21:822–827PubMedCrossRefGoogle Scholar
  70. Woodley DT, Fan J, Cheng CF, Li Y, Chen M, Bu G, Li W (2009) Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. J Cell Sci 122:1495–1498PubMedCrossRefGoogle Scholar
  71. Yu X, Harris SL, Levine AJ (2006) The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 66:4795–4801Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Wei Li
    • 1
    • 2
  • Kathryn O’Brien
    • 2
  • David T. Woodley
    • 2
  • Mei Chen
    • 2
  1. 1.1441 Eastlake Avenue, Room-6320Los AngelesUSA
  2. 2.The Department of Dermatology and the USC/Norris Comprehensive Cancer CenterThe University of Southern California Keck School of MedicineLos AngelesUSA

Personalised recommendations